Revolution Medicines Inc (RVMD) is a clinical-stage precision oncology company focused on developing therapies to target RAS and mTOR-driven cancers. The company utilizes its proprietary drug discovery and development engine to create small molecule therapeutics that inhibit the activity of oncogenic proteins and pathways. Revolution Medicines was founded in 2014 and is headquartered in Redwood City, California.
Revolution Medicines’ lead product candidate, RMC-4630, is an orally available small molecule inhibitor of the SHP2 protein, a key mediator of multiple oncogenic signaling pathways. The company is developing RMC-4630 for the treatment of RAS-driven cancers, including non-small cell lung cancer and colorectal cancer. Revolution Medicines is also developing RMC-5552, an inhibitor of mTORC1, for the treatment of patients with advanced solid tumors.
In addition to its clinical-stage programs, Revolution Medicines has a preclinical pipeline of novel small molecule inhibitors targeting other oncogenic pathways. The company is also utilizing its drug discovery engine to identify and validate new targets for the development of precision oncology therapeutics.
Revolution Medicines went public in February 2020 and is traded on the NASDAQ stock exchange under the ticker symbol “RVMD”. As of February 18, 2023, Revolution Medicines has a market capitalization of approximately $2.6 billion.
|
